WHO must continue its work on access to medicines in developing countries
Where WHO needs to be much more active is the issue of drug research and development, which is currently run according to market incentives to meet the needs of the few, with total disregard to the immediate, unmet health needs of the vast majority. Doctors in the developing world urgently need new...
Gespeichert in:
Veröffentlicht in: | The Lancet (British edition) 2003-01, Vol.361 (9351), p.3-3 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 3 |
---|---|
container_issue | 9351 |
container_start_page | 3 |
container_title | The Lancet (British edition) |
container_volume | 361 |
creator | Ford, Nathan Piédagnel, Jean-Michel |
description | Where WHO needs to be much more active is the issue of drug research and development, which is currently run according to market incentives to meet the needs of the few, with total disregard to the immediate, unmet health needs of the vast majority. Doctors in the developing world urgently need new tools such as a new effective and affordable meningitis vaccine, new drugs to combat malarial drug resistance and replace the ineffective and toxic drugs for Chagas, and new medicines for tropical diseases like Dengue fever and Buruli ulcer that remain totally untreatable. WHO should be setting the research agenda according to unmet needs and clearly advocating for public sector involvement to ensure these needs are met. As an urgent first step, WHO should start formulating recommendations to ensure the research and development of drugs, diagnostics, and vaccines within existing trade relationships. A treaty on research and development such as is being elaborated for tobacco could be formulated to create a system of burden sharing. |
doi_str_mv | 10.1016/S0140-6736(03)12173-3 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72962134</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0140673603121733</els_id><sourcerecordid>72962134</sourcerecordid><originalsourceid>FETCH-LOGICAL-c388t-432c8b65e7eab597cf1c985d26f02f3a9d8774cb9b9fae150e6d191b60ed5aed3</originalsourceid><addsrcrecordid>eNqFkE1LHTEUhoNU9PrxEyyhi6KL0ZxkkkxWUqR-gOBCpd2FmcyZEr03uSYzFv-90Xux0I2rs3ne9z08hBwAOwYG6uSWQc0qpYU6ZOIIOGhRiQ0yg1rXlaz17y9k9oFsk52cHxhjtWJyi2wDlxyY4DNy9evyhi6mPFIXw-jDhNSPmf6N6ZHGQFvnMGc6RrrA3jsfMFMfaI_POI9LH_6U2BTG5DHvkc2hnWfcX99dcn_-8-7ssrq-ubg6-3FdOdE0Y1UL7ppOSdTYdtJoN4Azjey5GhgfRGv6RuvadaYzQ4sgGaoeDHSKYS9b7MUu-b7qXab4NGEe7cJnh_N5GzBO2WpuFAdRF_Dbf-BDnFIov1kwhnFoGlUguYJcijknHOwy-UWbXiww-ybavou2bxYtE_ZdtBUl93VdPnVFzb_U2mwBTlcAFhfPHpPNzmNwRWNCN9o--k8mXgG-mIzn</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>199021886</pqid></control><display><type>article</type><title>WHO must continue its work on access to medicines in developing countries</title><source>MEDLINE</source><source>Business Source Complete</source><source>ScienceDirect Journals (5 years ago - present)</source><source>ProQuest Central UK/Ireland</source><creator>Ford, Nathan ; Piédagnel, Jean-Michel</creator><creatorcontrib>Ford, Nathan ; Piédagnel, Jean-Michel</creatorcontrib><description>Where WHO needs to be much more active is the issue of drug research and development, which is currently run according to market incentives to meet the needs of the few, with total disregard to the immediate, unmet health needs of the vast majority. Doctors in the developing world urgently need new tools such as a new effective and affordable meningitis vaccine, new drugs to combat malarial drug resistance and replace the ineffective and toxic drugs for Chagas, and new medicines for tropical diseases like Dengue fever and Buruli ulcer that remain totally untreatable. WHO should be setting the research agenda according to unmet needs and clearly advocating for public sector involvement to ensure these needs are met. As an urgent first step, WHO should start formulating recommendations to ensure the research and development of drugs, diagnostics, and vaccines within existing trade relationships. A treaty on research and development such as is being elaborated for tobacco could be formulated to create a system of burden sharing.</description><identifier>ISSN: 0140-6736</identifier><identifier>EISSN: 1474-547X</identifier><identifier>DOI: 10.1016/S0140-6736(03)12173-3</identifier><identifier>PMID: 12521032</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Advocacy ; Developing Countries ; Drug Industry - trends ; Drug resistance ; Health care access ; Humans ; LDCs ; Pharmaceuticals ; Public health ; Public Health - trends ; Public sector ; R&D ; Research & development ; Vaccines ; Vector-borne diseases ; World Health Organization</subject><ispartof>The Lancet (British edition), 2003-01, Vol.361 (9351), p.3-3</ispartof><rights>2003</rights><rights>Copyright Lancet Ltd. Jan 4, 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c388t-432c8b65e7eab597cf1c985d26f02f3a9d8774cb9b9fae150e6d191b60ed5aed3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/199021886?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3549,27923,27924,45994,64384,64386,64388,72340</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12521032$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ford, Nathan</creatorcontrib><creatorcontrib>Piédagnel, Jean-Michel</creatorcontrib><title>WHO must continue its work on access to medicines in developing countries</title><title>The Lancet (British edition)</title><addtitle>Lancet</addtitle><description>Where WHO needs to be much more active is the issue of drug research and development, which is currently run according to market incentives to meet the needs of the few, with total disregard to the immediate, unmet health needs of the vast majority. Doctors in the developing world urgently need new tools such as a new effective and affordable meningitis vaccine, new drugs to combat malarial drug resistance and replace the ineffective and toxic drugs for Chagas, and new medicines for tropical diseases like Dengue fever and Buruli ulcer that remain totally untreatable. WHO should be setting the research agenda according to unmet needs and clearly advocating for public sector involvement to ensure these needs are met. As an urgent first step, WHO should start formulating recommendations to ensure the research and development of drugs, diagnostics, and vaccines within existing trade relationships. A treaty on research and development such as is being elaborated for tobacco could be formulated to create a system of burden sharing.</description><subject>Advocacy</subject><subject>Developing Countries</subject><subject>Drug Industry - trends</subject><subject>Drug resistance</subject><subject>Health care access</subject><subject>Humans</subject><subject>LDCs</subject><subject>Pharmaceuticals</subject><subject>Public health</subject><subject>Public Health - trends</subject><subject>Public sector</subject><subject>R&D</subject><subject>Research & development</subject><subject>Vaccines</subject><subject>Vector-borne diseases</subject><subject>World Health Organization</subject><issn>0140-6736</issn><issn>1474-547X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkE1LHTEUhoNU9PrxEyyhi6KL0ZxkkkxWUqR-gOBCpd2FmcyZEr03uSYzFv-90Xux0I2rs3ne9z08hBwAOwYG6uSWQc0qpYU6ZOIIOGhRiQ0yg1rXlaz17y9k9oFsk52cHxhjtWJyi2wDlxyY4DNy9evyhi6mPFIXw-jDhNSPmf6N6ZHGQFvnMGc6RrrA3jsfMFMfaI_POI9LH_6U2BTG5DHvkc2hnWfcX99dcn_-8-7ssrq-ubg6-3FdOdE0Y1UL7ppOSdTYdtJoN4Azjey5GhgfRGv6RuvadaYzQ4sgGaoeDHSKYS9b7MUu-b7qXab4NGEe7cJnh_N5GzBO2WpuFAdRF_Dbf-BDnFIov1kwhnFoGlUguYJcijknHOwy-UWbXiww-ybavou2bxYtE_ZdtBUl93VdPnVFzb_U2mwBTlcAFhfPHpPNzmNwRWNCN9o--k8mXgG-mIzn</recordid><startdate>20030104</startdate><enddate>20030104</enddate><creator>Ford, Nathan</creator><creator>Piédagnel, Jean-Michel</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TT</scope><scope>0TZ</scope><scope>0U~</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88C</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>KB~</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20030104</creationdate><title>WHO must continue its work on access to medicines in developing countries</title><author>Ford, Nathan ; Piédagnel, Jean-Michel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c388t-432c8b65e7eab597cf1c985d26f02f3a9d8774cb9b9fae150e6d191b60ed5aed3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Advocacy</topic><topic>Developing Countries</topic><topic>Drug Industry - trends</topic><topic>Drug resistance</topic><topic>Health care access</topic><topic>Humans</topic><topic>LDCs</topic><topic>Pharmaceuticals</topic><topic>Public health</topic><topic>Public Health - trends</topic><topic>Public sector</topic><topic>R&D</topic><topic>Research & development</topic><topic>Vaccines</topic><topic>Vector-borne diseases</topic><topic>World Health Organization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ford, Nathan</creatorcontrib><creatorcontrib>Piédagnel, Jean-Michel</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>News PRO</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Global News & ABI/Inform Professional</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Newsstand Professional</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ford, Nathan</au><au>Piédagnel, Jean-Michel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>WHO must continue its work on access to medicines in developing countries</atitle><jtitle>The Lancet (British edition)</jtitle><addtitle>Lancet</addtitle><date>2003-01-04</date><risdate>2003</risdate><volume>361</volume><issue>9351</issue><spage>3</spage><epage>3</epage><pages>3-3</pages><issn>0140-6736</issn><eissn>1474-547X</eissn><coden>LANCAO</coden><abstract>Where WHO needs to be much more active is the issue of drug research and development, which is currently run according to market incentives to meet the needs of the few, with total disregard to the immediate, unmet health needs of the vast majority. Doctors in the developing world urgently need new tools such as a new effective and affordable meningitis vaccine, new drugs to combat malarial drug resistance and replace the ineffective and toxic drugs for Chagas, and new medicines for tropical diseases like Dengue fever and Buruli ulcer that remain totally untreatable. WHO should be setting the research agenda according to unmet needs and clearly advocating for public sector involvement to ensure these needs are met. As an urgent first step, WHO should start formulating recommendations to ensure the research and development of drugs, diagnostics, and vaccines within existing trade relationships. A treaty on research and development such as is being elaborated for tobacco could be formulated to create a system of burden sharing.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>12521032</pmid><doi>10.1016/S0140-6736(03)12173-3</doi><tpages>1</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0140-6736 |
ispartof | The Lancet (British edition), 2003-01, Vol.361 (9351), p.3-3 |
issn | 0140-6736 1474-547X |
language | eng |
recordid | cdi_proquest_miscellaneous_72962134 |
source | MEDLINE; Business Source Complete; ScienceDirect Journals (5 years ago - present); ProQuest Central UK/Ireland |
subjects | Advocacy Developing Countries Drug Industry - trends Drug resistance Health care access Humans LDCs Pharmaceuticals Public health Public Health - trends Public sector R&D Research & development Vaccines Vector-borne diseases World Health Organization |
title | WHO must continue its work on access to medicines in developing countries |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T21%3A08%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=WHO%20must%20continue%20its%20work%20on%20access%20to%20medicines%20in%20developing%20countries&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=Ford,%20Nathan&rft.date=2003-01-04&rft.volume=361&rft.issue=9351&rft.spage=3&rft.epage=3&rft.pages=3-3&rft.issn=0140-6736&rft.eissn=1474-547X&rft.coden=LANCAO&rft_id=info:doi/10.1016/S0140-6736(03)12173-3&rft_dat=%3Cproquest_cross%3E72962134%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=199021886&rft_id=info:pmid/12521032&rft_els_id=S0140673603121733&rfr_iscdi=true |